Pages that link to "Q34896542"
Jump to navigation
Jump to search
The following pages link to Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized c (Q34896542):
Displaying 13 items.
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (Q24187274) (← links)
- Tyrosine Kinase Inhibitors for the Elderly (Q26748567) (← links)
- Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer (Q26782255) (← links)
- miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma (Q36132797) (← links)
- Afatinib in squamous cell carcinoma of the head and neck (Q38829891) (← links)
- AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors. (Q41593135) (← links)
- Head and neck squamous cell carcinoma and human papillomavirus: epidemiology, treatment and future trends (Q48567230) (← links)
- Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure (Q49386937) (← links)
- Direct inhibition of RAS: Quest for the Holy Grail? (Q49721819) (← links)
- Effect of TLR4 on the growth of SiHa human cervical cancer cells via the MyD88-TRAF6-TAK1 and NF-κB-cyclin D1-STAT3 signaling pathways. (Q54094657) (← links)
- Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. (Q54979771) (← links)
- Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. (Q55509033) (← links)
- Radiotherapy plus EGFR inhibitors: synergistic modalities. (Q59606033) (← links)